RDY's Q4 Results in Detail Dr. Reddy's reported revenues under three segments — Global Generics, Pharmaceutical Services & Active Ingredients (PSAI) and Others. Global Generics revenues totaled INR 65.8 billion, down 13% year over year. The decrease was mainly due to lower North America generics sales, partly offset by broad-based growth across key markets supported by favorable foreign exchange movements. Key Takeaways Dr. Reddy's Laboratories Limited (RDY) reported fourth-quarter fiscal 2026 adjusted earn ...